TIDMAGY
Allergy Therapeutics PLC
14 May 2018
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics Publishes New Data Validating Mode of
Action and Unique Adjuvant Properties of its Patented Adjuvant,
Microcrystalline Tyrosine (MCT(R) ), in The Journal of
Immunology
Novel Findings Further Highlight the Effectiveness of MCT as
Alternative to Alum and its Potential Advantage in Allergy-Specific
Immunotherapy
WORTHING, United Kingdom, 14 May 2018 - Allergy Therapeutics
(AIM:AGY), a leading, fully-integrated commercial biotechnology
company specialising in allergy vaccines, today announces that new
data from a study investigating immune responses produced by
microcrystalline tyrosine (MCT(R) )-based vaccines as compared with
conventional aluminium hydroxide has been published online in The
Journal of Immunology. The findings demonstrate that, based on its
comparable strength and mechanism of Ag-specific IgG induction and
induction of T cell responses, MCT(R) is a suitable and flexible
alternative to aluminium hydroxide as an adjuvant in both
allergen-specific immunotherapy and infectious disease
applications. The study also demonstrated that MCT(R) -adjuvanted
allergens caused fewer anaphylactic reactions compared with
alum-adjuvanted allergens.
"These findings provide evidence of the effectiveness of MCT as
an adjuvant, confirming the mechanism of action underlying its
ability to induce a robust and sustained immunological response.
Additionally, the findings indicated a potentially favourable
profile for the use of MCT over alum in allergy-specific vaccines,"
said Matthias Kramer, M.D., Allergy Therapeutics' International
Medical Director and co-author of the paper. "We believe these data
highlight the significance of our differentiated proprietary
platform technology in the development of our growing suite of
cutting-edge, globally marketed ultra-short course allergy
vaccines."
This is the first study to report the mechanism of action by
which MCT governs the immunologic response after exposure to an
antigen and protection against anaphylaxis in an allergic model.
The results illustrate upregulation of IgG antibody responses and a
higher IgE:IgG ratio in MCT-based immunotherapy compared with
Alum-based immunotherapy. A high IgE:IgG ratio has been reported to
be a positive predictive marker for allergen immunotherapy in
humans.
Further evaluation in this study indicated that MCT facilitates
robust adaptive T cell responses with associated IFN-<GAMMA>
(interferon gamma) and TNF-<ALPHA> (tumour necrosis factor
alpha), which is in line with previous studies illustrating
protective efficacy in influenza and malaria applications(1, 2) .
Meanwhile, studies in a cancer (melanoma) model are underway.
A link to publication is here:
www.jimmunol.org/content/200/9/3151
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Stern Investor Relations
+1 212 362 1200
Christina Tartaglia
Christina@sternir.com
Notes for editors:
About Microcrystalline Tyrosine (MCT(R) )
MCT has been developed by the research division of Allergy
Therapeutics, Bencard Adjuvant Systems, and comprises the depot in
the group's marketed allergen-specific immunotherapy vaccines.
MCT(R) has been designed to provide defined particle size and
morphology along with strong antigen binding capacity to enhance
its use as a powerful immune system potentiator.
Many existing adjuvants persist long after administration,
whereas MCT(R), being based upon naturally derived amino acids, is
biodegradable with a half-life of 48 hours. Previous research has
illustrated that MCT(R) is consistently absorbed with antigens and
other adjuvants(3) , a feature that permits the creation of novel
adjuvant systems.
MCT has demonstrated enhanced protective immune responses
against infectious disease antigens and in a pre-clinical model,
MCT(R) enhanced specific IgG responses and protection(2) .
References
1 - Heath. M et al., Comparison of a novel microcrystalline
tyrosine adjuvant with aluminium hydroxide for enhancing
vaccination against seasonal influenza. BMC Infect Dis. 2017 Mar
27;17(1):232
2 - Microcrystalline Tyrosine (MCT(R) ): A Depot Adjuvant in
Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.
Cabral-Miranda et al., Vaccines 2017, 5, 32.
3 - Bell A.J. et al., The adsorption of allergoids and MPL to
MCT(R) in formulations for use in allergy immunotherapy. J Inorg
Bioch 152 (2015) 147 -153.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focused on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFKDDBPBKDDPD
(END) Dow Jones Newswires
May 14, 2018 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024